Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

New AI-derived model integrates longitudinal ctDNA and clinical data with digital pathology and tumor sequencing data, to refine recurrence risk assessment and outcomes prediction Signatera has ...

All Google Chrome users must ensure their browser is updated now as new security bypass confirmed. Updated January 8 with more news concerning Google Chrome web browser updates, this time involving a ...

Google recently decided that the freedom afforded by Android was a bit too much and announced developer verification, a system that will require developers outside the Google Play platform to register ...

Personalis has high upside potential if its MRD test gains Medicare reimbursement, but current revenue and margins are under pressure. The company faces declining pharma revenue, sustained cash burn, ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for identifying patients ...

MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly "minimal") residual disease (MRD). Once confined to the realm of ...

Chrome users are advised to update their browser immediately to fix a critical vulnerability that is being exploited to launch account takeover attacks. In some environments, this could even give ...

MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...

MRD negativity in MM patients correlates with improved survival, suggesting its potential as a surrogate marker for survival outcomes. Novel therapeutics complicate the assessment of PFS and OS, ...

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment strategies for TP53-mutant MDS and AML. A clinical trial evaluating duplex ...